Santos Carlos E's Form 4 filing
Legend Biotech CorpLEGN · filed Sep 23, 2026
- Accession no.
- 0002097065-26-000005
- Filed
- Sep 23, 2026, 4:15 PM ET
- Trade date
- Sep 21, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $49.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Santos Carlos ECIK 0002097065 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Ordinary Shares | AGrant or awardAcquired | +19,676 | $0.00 | $0 | 19,676 | Direct | |
| Sep 21, 2026 | Ordinary Shares | SSaleDisposed | −5,430 | $9.14F3 | −$49,630.2 | 14,246 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.